Clinical Trial Update: PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update exploring continuous combination of pegylated liposomal doxorubicin (PLD) with cyclophosphamide and Nab-Paclitaxel in HER2-positive breast …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• PLD-cyclophosphamide-Nab-P (pegylated liposomal doxorubicin + cyclophosphamide + nab-paclitaxel)

Snippet

Sponsor: Xijing Hospital | Conditions: Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Status: UNKNOWN